Sehouli J - Search Results

1

Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients.

Sehouli J, Fotopoulou C, Erol E, Richter R, Reuss A, Mahner S, Lauraine EP, Kristensen G, Herrstedt J, du Bois A, Pfisterer J. Sehouli J, et al. Eur J Cancer. 2015 May;51(7):825-32. doi: 10.1016/j.ejca.2015.01.008. Epub 2015 Mar 11. Eur J Cancer. 2015. PMID: 25771433

2

First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study.

Sehouli J, Stengel D, Elling D, Ortmann O, Blohmer J, Riess H, Lichtenegger W; Ovarian Cancer Study Group of the Nordostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO). Sehouli J, et al. Gynecol Oncol. 2002 May;85(2):321-6. doi: 10.1006/gyno.2002.6623. Gynecol Oncol. 2002. PMID: 11972395 Clinical Trial.

3

A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy.

Sehouli J, Stengel D, Oskay G, Camara O, Hindenburg HJ, Klare P, Blohmer J, Heinrich G, Elling D, Ledwon P, Lichtenegger W; NOGGO study group. Sehouli J, et al. Ann Oncol. 2002 Nov;13(11):1749-55. doi: 10.1093/annonc/mdf294. Ann Oncol. 2002. PMID: 12419747 Free article. Clinical Trial.

4

A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum.

Sehouli J, Stengel D, Oskay G, Blohmer J, Kaubitzsch S, Lichtenegger W. Sehouli J, et al. J Obstet Gynaecol Res. 2003 Jun;29(3):123-31. doi: 10.1046/j.1341-8076.2003.00087.x. J Obstet Gynaecol Res. 2003. PMID: 12841693

5

[Conventional and experimental prognostic factors in ovarian cancer].

Sehouli J, Mustea A, Könsgen D, Lichtenegger W. Sehouli J, et al. Zentralbl Gynakol. 2004 Oct;126(5):315-22. doi: 10.1055/s-2004-832305. Zentralbl Gynakol. 2004. PMID: 15478050 Review. German.

6

Why institutions do not participate in ovarian cancer trials -- results from a survey in Germany.

Sehouli J, Kostromitskaia J, Stengel D, du Bois A. Sehouli J, et al. Onkologie. 2005 Jan;28(1):13-7. doi: 10.1159/000082183. Onkologie. 2005. PMID: 15591726

7

Review of gemcitabine-based combinations for platinum-resistant ovarian cancer.

Sehouli J. Sehouli J. Int J Gynecol Cancer. 2005 May-Jun;15 Suppl 1:23-30. doi: 10.1111/j.1525-1438.2005.15353.x. Int J Gynecol Cancer. 2005. PMID: 15839955 Free article. Review.

8

Expression of lysophosphatidic acid acyltransferase beta (LPAAT-beta) in ovarian carcinoma: correlation with tumour grading and prognosis.

Niesporek S, Denkert C, Weichert W, Köbel M, Noske A, Sehouli J, Singer JW, Dietel M, Hauptmann S. Niesporek S, et al. Among authors: sehouli j. Br J Cancer. 2005 May 9;92(9):1729-36. doi: 10.1038/sj.bjc.6602528. Br J Cancer. 2005. PMID: 15841084 Free PMC article.

9

[Ovarian cancer -- can peritoneal therapy be regarded as new standard?].

du Bois A, Schmalfeldt B, Meier W, Sehouli J, Pfisterer J. du Bois A, et al. Among authors: sehouli j. Zentralbl Gynakol. 2006 Aug;128(4):202-6. doi: 10.1055/s-2006-933460. Zentralbl Gynakol. 2006. PMID: 16835814 German.

10

The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR.

Pfisterer J, du Bois A, Sehouli J, Loibl S, Reinartz S, Reuss A, Canzler U, Belau A, Jackisch C, Kimmig R, Wollschlaeger K, Heilmann V, Hilpert F. Pfisterer J, et al. Among authors: sehouli j. Ann Oncol. 2006 Oct;17(10):1568-77. doi: 10.1093/annonc/mdl357. Ann Oncol. 2006. PMID: 17005631 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

785 results

Search Page

Filters